Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 6/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27663532 | 1.00 | KMT2A (0.41) | KMT2AMEN1ACHESRD5A1SRD5A2 | |
| SCHEMBL27683240 | 0.88 | ABCB1 (0.41) | KMT2AMEN1SRD5A1SRD5A2LMNA | |
| SCHEMBL6446938 | 0.88 | MEN1 (0.40) | KMT2AMEN1SRD5A1SRD5A2SMN1; SMN2 | |
| SCHEMBL6444908 | 0.88 | MEN1 (0.40) | KMT2AMEN1SRD5A1SRD5A2SMN1; SMN2 | |
| SCHEMBL27663534 | 0.85 | CYP19A1 (0.45) | KMT2AMEN1LMNAESR1SMN1; SMN2 | |
| SCHEMBL6446726 | 0.83 | CYP2C9 (0.40) | KMT2AMEN1LMNANR3C1 | |
| SCHEMBL6444178 | 0.83 | CYP2C9 (0.40) | KMT2AMEN1LMNANR3C1 | |
| SCHEMBL12370186 | 0.83 | CYP3A4 (0.54) | KMT2AMEN1LMNASHBGCYP19A1 | |
| SCHEMBL11513033 | 0.83 | CYP3A4 (0.54) | KMT2AMEN1LMNASHBGCYP19A1 | |
| SCHEMBL11513028 | 0.83 | CYP3A4 (0.54) | KMT2AMEN1LMNASHBGCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3773730-A1 | DRUG DELIVERY FORMULATIONS | The Regents of The University of California (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210000744-A1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019191132-A1 | DRUG DELIVERY FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-03 | — | — | WO | disclosed |
| US-9161911-B2 | Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders | DEPOMED, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20100040689-A1 | GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERS | DEPOMED, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000744-A1 | DRUG DELIVERY FORMULATIONS | PGR, FKBP1A, LPXN | KMT2A 1886/4885MEN1 301/4885ACHE 3378/4885 |
| US-20100040689-A1 | GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERS | SLC18A2, SLC18A3, SLC6A2 | KMT2A 966/4885MEN1 1430/4885ACHE 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.